Select Your Region

We noticed you visit this page from United States. Please select your preferred region to continue

skip to content

Country Selector

Based on your location

Europe

North America

Latin America

Asia-Pacific

Healthcare Professional Verification

This section contains medical information for licensed healthcare professionals only. Please confirm your professional status to continue.

Carbohydrate Deficient Transferrin (CDT)

The most reliable excessive chronic alcohol marker.

Published date: 3/8/2021 | Modified date: 6/9/2026

About CDT

Chronic excessive alcohol consumption is a major public health concern, and early detection and monitoring are essential to improving patient outcomes and reducing alcohol‑related complications and healthcare costs. Carbohydrate‑Deficient Transferrin (CDT) is the IFCC‑recommended biomarker for reliably assessing chronic alcohol intake.

Sebia’s CAPI 3 CDT and MINICAP CDT assays quantify CDT in serum using capillary electrophoresis, a high‑resolution technique that separates transferrin isoforms according to their degree of sialylation. During analysis, transferrin is resolved into five principal fractions:

  • Asialotransferrin (non‑sialylated)
  • Disialotransferrin
  • Trisialotransferrin
  • Tetrasialotransferrin
  • Pentasialotransferrin

The CDT IFCC value (%) is automatically calculated based on the calibration curve of disialotransferrin. When CDT IFCC is not activated, a classic CDT (%) value is automatically computed using the low‑sialylated isoforms (disialotransferrin ± asialotransferrin, when present).

Interpretation is straightforward:

  • CDT IFCC > 2% is considered abnormal and indicative of chronic alcohol abuse.
  • For the classic CDT method, values > 1.6% are abnormal and likewise indicative of chronic alcohol abuse.

Key benefits

A proven and standardized biomarker for detecting chronic excessive alcohol consumption..
  • Simple, secured and accurate CDT measurement

    Normal clinical result : CDT IFCC ≤ 1.7% / Forensic positive result: CDT IFCC > 2%

  • Reduced hands-on time

    Ready to use reagents, no sample pre-treatment and no need for additional total transferrin measurement.

  • Automatic measurement with visualization of all transferrin isoforms

    Potential analytical and genetic interferences—such as transferrin variants, congenital disorders of glycosylation (CDG), or curve abnormalities seen in cirrhotic profiles—can be identified, helping prevent incorrect result reporting

  • Scalable solution to fit all lab’s configuration

    CDT is available on MINICAP and CAPILLARYS family offering multiple configurations for streamlined workflow.

  • Yearly IFCC

    certification renewal

Main characteristics

Test principle

The CAPI 3 CDT and MINICAP CDT assays operate on the principle of free‑solution capillary electrophoresis. In this system, transferrin isoforms are separated within silica capillaries according to their electrophoretic mobility and the electroosmotic flow generated under high voltage in an alkaline buffer. Detection is performed directly during migration through ultraviolet absorbance.

All analytical steps are fully automated. Sample preparation, including dilution with a dedicated diluent that ensures complete iron saturation of transferrin, is carried out automatically by the system.

Sample type

A serum sample is required to perform the CDT test. In forensic settings, serum provides clear advantages over matrices such as hair or urine, ensuring better sample integrity and analytical reliability while reducing the risk of tampering or fraud.

Performances

                                          Throughput (tests/hour)*

CDT

  • CAPILLARYS 3 OCTA                     49
  • CAPILLARYS 3 TERA                     73
  • CAPILLARYS 3 TERA MC3**        211
  • MINICAP FLEX-PIERCING             10

Full traceability and positive ID for samples and reagents.

*Firmware-dependent; contact your local Sebia representative for current information.
**Maximum Capacity or MC designation refers to Tube Loader CAPILLARYS 3 - P/N: 1249 and Rack Conveyor CAPILLARYS 3 - P/N: 1250 associated with CAPILLARYS 3 TERA - P/N: 1246.

Product details

  • CAPI 3 CDT – P/N: 2509
  • MINICAP CDT – P/N: 2208

Knowledge & Science

No content available.

CDT test can be performed on the following instruments

This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.

Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.